thumbnail image
Operator of 'Pilleye', the world's #1 pill counting app
Completes Pre-Series A investment round
Funds to be used for developing an automated drug inventory management solution


Medility, a startup leading the digital transformation (DX) of pharmacies with artificial intelligence (AI) technology, has completed its Pre-Series A funding round. The new investment amount is 5.6 billion won.

The round was led by KB Investment, with Korea Development Bank (KDB) and Kakao Ventures participating as new investors. Existing seed investor, BA Partners, also participated in the follow-on investment.


Medility provides Pilleye, the world's #1 pill counting app. Developed in 2021, Pilleye has now secured over 400,000 subscribers in 225 countries worldwide, and its monthly active users have surpassed 150,000.

The company anticipates reaching its break-even point (BEP) by the end of the year through a partial transition to a paid model.


The PillEye app uses object recognition technology to count up to 1,000 pills with 99.99% accuracy from a single smartphone photo. According to the company,

it has saved healthcare providers more than 1.3 million hours that would otherwise have been spent manually counting pills.


With the latest investment, Medility plans to develop an automated inventory management solution for pharmaceuticals.

The company is also working to enhance its automated drug inspection solution, which was selected as a TIPS project by the Ministry of SMEs and Startups last year.

The device for this inspection solution has experienced delays in development, with its launch now targeted for the first half of next year.


CEO Sang-eon Park, who graduated from Yeungnam University’s College of Pharmacy and ran a pharmacy for 10 years, founded Medility in November 2020. The company’s target is the global pharmacy market.

There are an estimated 1.6 million pharmacists worldwide and more than 3.5 million dispensing staff including support personnel. Starting with its pill counting app, Medility aims to provide pharmacies with automation solutions for drug inspection, inventory management, and ordering.

CEO Park stated, “Despite the difficult capital environment, our AI object recognition technology and the market potential for pharmacy digital transformation have been well received.

Building on our experience developing PillEye, which is used by pharmacists worldwide, we aim to become a company that drives the digital transformation of global pharmacies—from automated drug inspection to inventory and order management.”

Featured Posts